1	Title: Investigating SARS-CoV-2 surface and air contamination in an acute healthcare
2	setting during the peak of the COVID-19 pandemic in London
3	
4	Running Title: SARS-CoV-2 air and surface contamination
5	
6	Authors: Jie Zhou, ^{1*} Jonathan A. Otter, ^{2,3*} James R. Price, ^{2,3} Cristina Cimpeanu, ³ Danel
7	Meno Garcia, ³ James Kinross, ^{3,4} Piers R Boshier, ^{3,4} Sam Mason, ^{3,4} Frances Bolt, ^{2,3} Alison H.
8	Holmes, ^{2,3} Wendy S. Barclay ¹
9	* Joint first authors
10	Affiliations:
11	1. Department of Infectious Disease, Imperial College London, London, UK, W2 1PG.
12	2. National Institute for Healthcare Research Health Protection Research Unit (NIHR
13	HPRU) in HCAI and AMR, Imperial College London & Public Health England,
14	Hammersmith Hospital, Du Cane Road, W12 0HS.
15	3. Imperial College Healthcare NHS Trust, St. Mary's Hospital, Praed Street, London,
16	W2 1NY, UK.
17	4. Department of Surgery and Cancer, Imperial College London, London, UK, W2 1NY.
18	
19	Corresponding author: Dr Jonathan Otter, Imperial College London, NIHR Health
20	Protection Research Unit, Hammersmith Hospital, Du Cane Road, W12 0HS. Tel: 020 331
21	33271, Email: j.otter@imperial.ac.uk.
22	
23	Key words: SARS-CoV-2, COVID-19, transmission, air contamination, surface
24	contamination
25	Key points: The role of surface and air contamination in SARS-CoV-2 transmission was
26	evaluated in a London hospital. Whilst SARS-CoV-2-RNA was detected no viable virus was
27	recovered. This underlines the potential risk of environmental contamination and the need
28	for effective IPC practices.

29 Author contributions

30 All authors met the ICMJE criteria for authorship. JZ and JAO conceived the study, collected 31 and analysed data, and wrote the manuscript; JRP conceived the study, collected data, and 32 contributed to the manuscript; CP, DMG, PRB, SM collected data and contributed to the 33 manuscript; FB, AHH, and ASB conceived the study, analysed data, and contributed to the 34 manuscript. JAO is the study guarantor. 35 36 ABSTRACT 37 38 Background: Evaluation of SARS-CoV-2 surface and air contamination during the COVID-39 19 pandemic in London. 40 Methods: We performed this prospective cross-sectional observational study in a multi-site 41 London hospital. Air and surface samples were collected from seven clinical areas, occupied by patients with COVID-19, and a public area of the hospital. Three or four 1.0 m³ air 42 43 samples were collected in each area using an active air sampler. Surface samples were 44 collected by swabbing items in the immediate vicinity of each air sample. SARS-CoV-2 was 45 detected by RT-qPCR and viral culture; the limit of detection for culturing SARS-CoV-2 from 46 surfaces was determined.

47 **Results**: Viral RNA was detected on 114/218 (52.3%) of surfaces and 14/31 (38.7%) air 48 samples but no virus was cultured. The proportion of surface samples contaminated with 49 viral RNA varied by item sampled and by clinical area. Viral RNA was detected on surfaces 50 and in air in public areas of the hospital but was more likely to be found in areas immediately 51 occupied by COVID-19 patients than in other areas (67/105 (63.8%) vs. 29/64 (45.3%) (odds 52 ratio 0.5, 95% confidence interval 0.2-0.9, p=0.025, Chi squared test)). The high PCR Ct 53 value for all samples (>30) indicated that the virus would not be culturable. 54 Conclusions: Our findings of extensive viral RNA contamination of surfaces and air across 55 a range of acute healthcare settings in the absence of cultured virus underlines the potential

- risk from environmental contamination in managing COVID-19, and the need for effective
- 57 use of PPE, physical distancing, and hand/surface hygiene.

59 **INTRODUCTION**

60

Since it was identified in Wuhan, China, in late 2019, the severe acute respiratory syndrome coronavirus (SARS-CoV-2) has rapidly spread around the world, resulting in a coronavirus disease 2019 (COVID-19) pandemic.[1] Experience from previous SARS and influenza outbreaks and emerging evidence for SARS-CoV-2 suggests droplet and contact spread as primary transmission routes.[1, 2] Additionally, there is evidence that airborne spread can occur during aerosol generating procedures.[1, 2]

67

68 In-hospital transmission to patients and healthcare workers was a key feature of SARS-CoV-69 1.[1, 3] Hospital-onset COVID-19 infection has been reported, probably due to inadequate 70 implementation of effective infection prevention and control measures.[4] The dynamics of 71 transmission in the health care environment are unclear and likely to be multifactorial. 72 Contaminated surfaces and air are recognised as a key part of the transmission dynamic of 73 SARS, MERS, influenza, and other organisms in hospitals.[1, 2, 5] Laboratory evidence 74 suggests that the SARS-CoV-2 virus can survive on dry surfaces and in aerosols for days to 75 weeks, particularly on non-porous surfaces.[6, 7] Furthermore, SARS-CoV-2 RNA has been 76 detected on surfaces and in the air in hospitals that are caring for patients with COVID-19.[8-77 16]

78

79 However, our understanding of the role of surface and air contamination in the transmission 80 of SARS-CoV-2 is limited. Most studies to date have relied on PCR to detect SARS-CoV-2 81 on surfaces and in air, and have not attempted to culture live virus thereby limiting the ability 82 to interpret the relevance of detection by PCR; most studies published so far have focussed 83 upon one geographical region (Asia), and included a limited selection of clinical and non-84 clinical areas were included with no evidence from operating theatre environments.[8, 9, 11, 85 12, 14, 15] In mid-April 2020, the UK was experiencing the first wave of the COVID-19 86 pandemic. During this period, there was evidence for hospital acquired infections with

COVID-19.[17] Therefore, to inform and optimise infection prevention and control interventions, we evaluated surface and air contamination across a range of clinicallyrelevant locations (including operating theatres) and public areas during the peak of the COVID-19 pandemic in London, using both RT-PCR and viral culture to detect SARS-CoV-2. We also performed supporting laboratory experiments to provide evidence on the viability of SARS-CoV-2 on surfaces, with associated limits of detection to qualify our findings.

93

94 METHODS

95

96 Setting

97 Sample collection for this prospective cross-sectional study was performed between April 2nd 98 and 20th 2020 on selected wards at a large North West London teaching hospital group 99 comprising five hospitals across four sites with 1,200 acute beds, which prior to the 100 pandemic undertook 1.2 million episodes of patient contact per year. Most sampling was 101 conducted on one hospital site during the peak of the COVID-19 pandemic (Supplemental 102 Figure 1) when most patients were managed in cohort wards.

103

104 Clinical areas selected for air and surface sampling

Seven clinical areas and a public area of the hospital were selected to represent a range ofclinical environments within our hospital group. These included:

- Adult emergency department, which included sections dedicated for suspected and confirmed COVID-19 patients (with 19 cubicles and a 6-bedded resuscitation bay)
 and for patients not suspected to have COVID-19 (with a two cubicle-bay, and two four-cubicle bays).
- A 16-bedded COVID-19 cohorting adult acute admissions unit with four four-bedded
 bay.

113	• A 32-bedded COVID-19 cohorting adult intensive care unit with four four-bedded
114	bays and 16 single rooms.
115	Theatres during tracheostomy procedures.
116	• Two adult COVID-19 cohort wards: one 20-bed ward with four four-bedded bays and
117	four single rooms, and one 19-bed ward with a nine-bedded bay, an 8 bedded-bay
118	and two single rooms.
119	• An adult ward area including a 6-bedded bay converted into a negative pressure
120	area for management of continuous positive airway pressure (CPAP) on patients with
121	COVID-19.
122	The entrance and public area of the main hospital building.
123	
124	All inpatient wards were fully occupied by patients with COVID-19 at the time of sampling,
125	apart from the Emergency Department. In the part of the Emergency Department dedicated
126	for patients with confirmed or suspected COVID-19, two of the cubicles were occupied and
127	one patient was in the ambulatory wait area at the time of sampling. These areas were
128	disinfected daily using a combined chlorine-based detergent/disinfectant (Actichlor Plus,
129	Ecolab), with an additional twice daily disinfection of high touch surfaces using the same
130	detergent/disinfectant.
131	
132	In each of these clinical areas, four air samples were collected (five air samples were
133	collected in the Emergency Department, and three in public areas of the hospital). Surfaces
134	in the immediate vicinity of each air sample that were considered to be touched frequently by

135 staff or patients were sampled. These included bed rails, clinical monitoring devices (blood 136 pressure monitors), ward telephones, computer keyboards, clinical equipment (syringe 137 pumps, urinary catheters), hand-cleaning facilities (hand washing basins, alcohol gel 138 dispensers). In each clinical area, sampling was performed in both patient (i.e. bays and 139 single rooms) and non-patient care areas (i.e.nursing stations and staff rooms).

Environmental sampling was conducted during three tracheostomy procedures. During the first procedure, air sampling was performed before and during the procedure; for the other procedures, air sampling was performed during the procedure only.

143

144 Sampling methods

145 Air sampling was performed using a Coriolis µ air sampler (referred to as Coriolis hereafter) 146 (Bertin Technologies), which collects air at 100–300 litres per minute (LPM). After 10 min 147 sampling at 100 LPM, a total of 1.0 m³ air was sampled into a conical vial containing 5 mL 148 Dulbeccos's minimal essential medium (DMEM). Surface samples were collected by 149 swabbing approximately 25 cm² areas of each item using flocked swabs (Copan, US) 150 moistened in DMEM. Temperature, humidity and time of day were recorded at the time of 151 sampling. In all clinical settings, samples were taken in order from the lowest to highest 152 perceived risk of SARS-CoV-2 contamination.

153

154 Detection and quantification of SARS-CoV-2 viral RNA genome and viral culture

155 Viral RNA detection and absolute quantification was performed using quantitative real-time 156 reverse transcription polymerase chain reaction (RT-qPCR). Samples were extracted from 157 140 µL of the DMEM medium using the QIAamp viral RNA mini Kit according to the 158 manufacturer's instructions (Qiagen, Germany). Negative controls (water) were extracted 159 and included in the PCR assays. SARS-CoV-2 viral RNA was detected using AgPath-ID 160 One-Step RT-PCR Reagents (Life Technologies) with specific primers and probes targeting the envelop (E) gene.[18] The number of SARS-CoV-2 virus E gene copies per m³ air and 161 162 copies per swab were calculated. All samples were run in duplicate.

163

Viral culture: Vero E6 (African Green monkey kidney) and Caco2 (human colon carcinoma) cells were used to culture virus from air and environmental samples. The cells were cultured in DMEM supplemented with heat inactivated fetal bovine serum (10%) and Penicillin/Streptomycin (10, 000 IU/mL &10, 000 µg/mL). For propagation, 200 µL of

168 samples were added to 24 well plates. After 5-7 days, cell supernatants were collected, and 169 RT-qPCR to detect SARS-CoV-2 performed as described above. Samples with at least one 170 log increase in copy numbers for the E gene (reduced Ct values relative to the original 171 samples) after propagation in cells were considered positive by viral culture.

172

173 We defined samples where both of the PCRs performed from an air or surface sample

detected SARS-CoV-2 RNA as positive, and samples where one of the two PCRs performed

175 from an air or surface sample detected SARS-CoV-2 RNA as suspected.

176

177 We performed a laboratory experiment to determine the limit of detection for culturing SARS-178 CoV-2 dried on surfaces. A dilution series from solution containing 8.25x10⁶ PFU/mL SARS-CoV-2 (titred by plaque assay in Vero cells) from 10^{-3} to 10^{-6} (covering Ct values from 26 to 179 180 36) was produced in DMEM and 50 µL inoculated in triplicate onto the surface of plastic 181 (standard keyboard key) or stainless steel (2 x 1 x 0.2 cm) pieces. The inoculated surfaces 182 were dried in a safety cabinet for 2 hours after which they were visibly dry. They were then 183 sampled using flocked swabs. Swabs were deposited into 1.5 mL of DMEM for 1 hour. RT-184 qPCR was used to determine viability following 7 days of culture as follows. 140 μL was 185 used for RNA extraction and qPCR immediately (0 days post inoculation, dpi) and after 186 incubation for 7 days in a 24-well plate with VeroE6 cells (7 dpi). Samples with an increase 187 in copy numbers for the E gene (reduced Ct values relative to the original samples) after 188 propagation in Vero E6 cells were considered positive by viral culture.

189

190 Statistical analysis

A Chi square test was used to compare the proportion of environmental samples (surfaces or air) that were positive or suspected for SARS-CoV-2 RNA in areas immediately occupied by patients with COVID-19 with other areas. The mean concentration of air and surface contamination in each of the areas was log transformed and then compared by one-way ANOVA followed by Tukey's multiple comparisons test.

196

197 Ethics approval

198 The work was registered locally as an NHS service evaluation (#434).

199

200 RESULTS

201

114/218 (52.3%) of surface samples were suspected (91/218 (41.7%)) or positive (23/218
(10.6%)) for SARS-CoV-2 RNA but no virus was cultured (Table 1). The proportion of
surface samples contaminated varied by item, with suspected or positive RNA samples
identified on >80% of computer keyboards/mice, alcohol gel dispensers, and chairs, and >50%
of toilet seats, sink taps, and patient bedrails (Figure 1). A similar pattern was observed in air
samples; no virus was cultured, but 14/31 (38.7%) of samples were suspected (12/31
(38.7%)) or positive 92/31 (6.4%)) for SARS-CoV-2 RNA (Table 1).

209

210 SARS-CoV-2 RNA was detected in air samples from all eight areas tested with levels 211 ranging from 10^1 to 10^3 genome copies / m³ (Table 1); there was no significant difference in 212 mean viral RNA concentration across the eight areas tested (p=0.826). Similarly, SARS-213 CoV-2 RNA was detected in surface samples from all eight areas tested, with levels ranging 214 from 10¹ to 10⁴ copies per swab (Figure 2). There was a significant difference in the mean 215 SARS-CoV-2 surface viral load across the eight areas tested (p=0.004), with both Cohort 216 Ward A and the Temporary CPAP ward showing higher levels of viral RNA; Cohort Ward A 217 $(mean = 1.76 \log_{10} \text{ copies/swab}) > \text{Adult ICU}$ $(mean = 0.0018 \log_{10} \text{ copies/swab})$ (p = 0.015), 218 and the Temporary CPAP Ward (mean = $1.69 \log_{10} \text{ copies/swab}$) > Adult ICU (p = 0.016).

219

Several clinical areas where AGPs are commonly performed were sampled. A suspected positive air sample was collected in the resuscitation bay in the emergency department, where aerosol generating procedures are commonly performed (although had not been performed for more than two hours prior to sample collection). In a ward temporarily

converted for CPAP, SARS-CoV-2 RNA was detected from air within the negative pressure
CPAP bay, and outside the bay. No patient was undergoing CPAP at the time of sampling,
but one patient was undergoing high-flow nasal cannula (HFNC) oxygen therapy. In the
adult ICU, 3/4 air samples were suspected or positive. In operating theatres, 1/3 air samples
collecting during three tracheostomy procedures was positive.

229

SARS-CoV-2 RNA was detected in surface and air samples in parts of the hospital hosting staff but not being used for direct patient care, including the staff room in the ICU, the nursing station outside of the CPAP unit, and in the hospital main entrance and public toilets. However, positive or suspected air and surface samples were significantly more likely to be found in areas immediately occupied by COVID-19 patients than in other areas (67/105 (63.8%) in areas immediately occupied by COVID-19 patients vs. 29/64 (45.3%) in other areas (odds ratio 0.5, 95% confidence interval 0.2-0.9, p=0.025).

237

Since viable virus was not cultured from any of the air or surface samples, we performed laboratory experiments to determine the limit of detection of SARS-CoV-2 dried onto surfaces. Viable SARS-CoV-2 virus could be cultured from experimentally contaminated dried surfaces with a Ct value <30; this was consistent for plastic and metal test surfaces (Table 2). In our study, all surface and air samples from the hospital environment had a Ct value >30.

244

245 **DISCUSSION**

246

SARS-CoV-2 RNA was detected frequently from surface and air samples but we did not identify viable virus in any surface or air sample. Furthermore, our simulated laboratory studies showed that the RNA levels detected on environmental surfaces in the hospital were lower than the minimum that can be cultured from surfaces two hours after virus is deposited. SARS-CoV-2 RNA was identified across the eight areas that we tested, including

areas of the hospital not used to care for patients with COVID-19 (e.g. public areas of the
hospital). However surface and air contamination was significantly more frequent in areas
immediately occupied by COVID-19 patients than in other areas.

255

256 A direct comparison between our findings and other studies that have evaluated 257 contamination of surfaces and air with SARS-CoV-2 is not possible due to differences in: 258 environmental sampling strategy (including which clinical areas were included, which 259 surfaces were sampled, and where air samples were collected from); experimental methods 260 (including the method for sampling surfaces and the sampler used for air); the phase of the 261 pandemic during which sampling was performed; the physical layout of buildings and clinical 262 spaces (including the efficiency of air handling systems); individual patient characteristics 263 that have been shonwn to influence shedding of SARS-CoV-2 and other hospital pathogens 264 including the stage and severity of disease and site of infection; [4, 19] and the patient and 265 staff testing, and cleaning and disinfection protocols. Nonetheless, our finding of widespread 266 detection of viral RNA on surfaces (114/218, 52.3%) and to a lesser extent air (14/31, 267 38.7%) is broadly consistent with the findings of most others although the proportion of 268 surface and air samples positive for viral RNA is higher in our study.[8-13] For example, Ye 269 et al. performed PCR detection of surface contamination in a range of clinical settings in a 270 hospital caring for patients with COVID-19 in Wuhan, China.[9] Overall, 14% of 626 surface 271 samples were positive for viral RNA, with a higher proportion of surface samples positive in 272 the ICU (32% of 69 samples). However, other studies have identified very little or no 273 contamination of surfaces or air.[8, 10] Other studies have observed higher frequencies of 274 contamination in patient-care vs. non-patient-care areas, [8, 9, 11] and variation in the 275 frequency of contamination across different clinical areas, which is in line with our 276 findings.[9, 11] One surprising finding in our study was that the level of contamination on 277 surfaces in the ICU was lower than in a cohort general ward or in the temporary CPAP ward, 278 in contrast to other findings.[9] This may be because patients sampled in the ICU were on 279 closed circuit ventilation systems through cuffed endotracheal tubes, which may have a

280 lower risk of producing surface and air contamination than other ventilation systems such as

281 CPAP.

282

283 We did not identify viable virus on any surface or air sample. Few studies have attempted to 284 culture SAR-CoV-2 from healthcare environments, and no viable virus was detected.[10, 14] 285 Our laboratory study of the viability of virus dried on surfaces helps to qualify our findings 286 and the findings of others, suggesting that Ct values of >30 are unlikely to be culturable. 287 Bearing in mind that the viral RNA detected in the hospital setting might have been 288 deposited more than two hours previously, we cannot differentiate whether our inability to 289 culture virus from the samples is explained by the low RNA levels or the length of time since 290 deposition or both. It is also possible that virus was infectious but not culturable in the 291 laboratory.

292

293 Surface contamination was detected on a range of items. Computer keyboards, chairs, and 294 alcohol dispensers had the highest proportion of positive/suspected SAS-CoV-2 samples. 295 Other studies have also identified computer keyboards and/or mice as a risk for 296 contamination with SARS-CoV-2 RNA.[8, 9, 11] Many of the computers that we sampled 297 were in shared staff clinical areas (such as nursing stations), so this argues for frequent 298 disinfection of these items. The contamination of alcohol gel dispensers is unsurprising since 299 staff hands activate these before hand hygiene is performed. However, alcohol gel 300 dispensers should be included in routine cleaning and disinfection protocols or designed 301 such that they can be activated without touching.

302

We sampled several areas where aerosol generating procedures are commonly performed including the resuscitation bay in the emergency department, ICU, temporary CPAP ward, and operating theatres during tracheostomies. Positive or suspected air samples were identified in all of these clinical areas at a level of 10¹ to 10³ copies / m³. There was no difference in the viral load of the air across the eight areas sampled, which provides some

308 evidence that AGPs do not produce persistently high levels of air contamination. However, 309 we did not sample the air over time, and our air sampling method did not differentiate 310 particle size so we are unable to distinguish droplets from aerosols (< 5 µM). One recent 311 study evaluated contamination of the air with SARS-CoV-2 in a permanent hospital and in a 312 field hospital in Wuhan, China.[13] Viral culture was not performed, but viral RNA was 313 identified a low levels (in the 10^{1} - 10^{2} range copies per m³) in patient care areas, and was not 314 detected or detected in very low levels in public areas. Positive samples were identified in a 315 range of particle sizes, including those <5 µM, which would typically be considered as 316 aerosols.[2] It seems likely, therefore, that the positive and suspected air samples identified 317 in our study included a range of particle sizes spanning 5 µM, particularly in areas where 318 aerosol generating procedures are common.

319

Whilst we performed sampling in a temporary CPAP ward, no patient was undergoing CPAP at the time of sampling. However, one patient was undergoing HFNC during the time of sample, and air contamination was identified <1 m from this patient. A recent summary of evidence concludes that HFNC is a lower risk procedure in terms of aerosol generation than CPAP, which should be a topic for future studies.[20]

325

We identified contamination of surfaces and air during three tracheostomy procedures. Several studies and commentaries have evaluated the potential for various surgical procedures to produce aerosols for patients with COVID-19.[21-23] One study evaluated the spread of droplets during tracheostomies, although did not include sampling for SARS-CoV-2.[21] Whilst our methods did not include measurement of particle size, our findings highlight a potential theoretical risk of transmission of COVID-19 during these procedures. However, a larger sample size is required to understand this risk

333

334 Our study has important strengths and limitations. Strengths include our sampling strategy 335 encompassing contemporaneous surface and air samples from a range of clinical services

336 including both patient care and non-patient care areas, specifically, we included operating 337 theatres and areas dedicated to known and potential AGPs; each sample was tested using 338 PCR and also viral culture, and we performed laboratory viral culture experiments to quality 339 our findings; the sampling was conducted during the peak of the pandemic (and so likely 340 represents a worst-case scenario) in a European hospital group. Limitations include not 341 collecting patient samples to better understand how our findings links to patient samples, 342 particularly during tracheostomies and AGPs; no asymptomatic patient or staff testing 343 ongoing at the time of sampling, which means patients and staff without known COVID-19 344 could have been shedding SARS-CoV-2 and this would explain the detection of SARS-CoV-345 2 RNA in non-patient care areas; challenges in interpreting the significance of samples with 346 low viral loads, ; a lack of resolution of particle sizes for contamination of the air; and no 347 longitudinal sampling was performed so these findings represent a "snapshot".

348

349 Our findings may have implications for future policy and guidelines. Most international 350 guidelines recommend enhanced surfaces disinfection during the management of COVID-351 19. For example, Public Health England recommends enhanced disinfection using a 352 chlorine-based disinfectant (or a disinfectant with effectiveness against coronaviruses).[24] 353 Our finding of widespread RNA contamination of clinical areas used to care for patients with 354 COVID-19 supports the need for enhanced disinfection. Physical distancing is 355 recommended by most governments and personal protective equipment (PPE) is 356 recommended during contact with patients with COVID-19 plus higher levels of PPE for 357 performing aerosol generating procedures. Whilst we did not measure particle sizes during 358 our air sampling, our findings highlight a potential role for contaminated air in the spread of 359 COVID-19. Our finding of air contamination outside of clinical areas should be considered 360 when making respiratory PPE recommendations in healthcare settings.[25]

361

362 Whilst SAR-CoV-2 RNA was detected within healthcare environments, further research 363 linking patient, staff and environmental samples is required to better understand

364 transmission routes. Longitudinal environmental and clinical sampling across healthcare 365 settings is required to understand risk factors associated with viral shedding and 366 transmission. Our findings can be used to parameterise mathematical models of COVID-19 367 transmission. Finally, our methods can be used to assess the potential risk associated with 368 various procedures including some surgical and other procedures such as CPAP and 369 nebulisation of medications. Findings from these studies may prompt changes to PPE 370 recommendations for specific procedures, and the implementation of various innovative 371 tools and approaches to reduce viral shedding (such as "helmet CPAP").[26-28]

372

Whilst SARS-CoV-2 RNA was detected in clinical and non-clinical areas, no viable virus was recovered. These results are in line with other studies which have identified viral RNA but no viable SARS-CoV-2 within healthcare environments. Our findings of extensive viral RNA contamination of surfaces and air across a range of acute healthcare settings in the absence of cultured virus underlines the potential risk from surface and air contamination in managing COVID-19, and the need for effective use of PPE, physical distancing, and hand/surface hygiene.

380

381 ACKNOWLEDGEMENTS

We wish to acknowledge the staff teams and patients who supported this sampling duringthe peak of the challenges posed by this pandemic.

384

385 FUNDING

386 The authors would like to acknowledge the support of the NIHR Imperial Biomedical

387 Research Centre, the Health Research Health Protection Research Unit (NIHR HPRU) in

388 HCAI and AMR and the HPRU in Respiratory Infections at Imperial College.

389

390 The views expressed in this publication are those of the author(s) and not necessarily those

391 of the NHS, the National Institute for Health Research, the Department of Health and Social

- 392 Care or Public Health England. Professor Alison Holmes is a National Institute for Health
- 393 Research (NIHR) Senior Investigator. International Severe Acute Respiratory and Emerging
- 394 Infection Consortium (ISARIC) provided funding for JZ and laboratory materials used for this
- 395 study.
- 396

397 **REFERENCES**

- 3981.Wilder-Smith A, Chiew CJ, Lee VJ. Can we contain the COVID-19 outbreak with the399same measures as for SARS? The Lancet Infectious diseases, **2020**; 20: e102-e7.
- Otter JA, Donskey C, Yezli S, Douthwaite S, Goldenberg SD, Weber DJ. Transmission
 of SARS and MERS coronaviruses and influenza virus in healthcare settings: the
 possible role of dry surface contamination. The Journal of hospital infection, **2016**;
 92: 235-50.
- 4043.Gowri G, Philip C, Yee Sin L, et al. SARS Transmission and Hospital Containment.405Emerging Infectious Disease journal, **2004**; 10: 395.
- 4064.He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility407of COVID-19. Nature medicine, **2020**; 26: 672-5.
- 408 5. Otter JA, Yezli S, Salkeld JA, French GL. Evidence that contaminated surfaces
 409 contribute to the transmission of hospital pathogens and an overview of strategies
 410 to address contaminated surfaces in hospital settings. Am J Infect Control, 2013; 41:
 411 S6-S11.
- 412 6. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of
 413 SARS-CoV-2 as Compared with SARS-CoV-1. The New England journal of medicine,
 414 2020; 382: 1564-7.
- 4157.Chin AWH, Chu JTS, Perera MRA, et al. Stability of SARS-CoV-2 in different416environmental conditions. The Lancet Microbe, **2020**; 1: e10.
- 417 8. Wu S, Wang Y, Jin X, Tian J, Liu J, Mao Y. Environmental contamination by SARS-CoV418 2 in a designated hospital for coronavirus disease 2019. Am J Infect Control, **2020**:
- 419 9. Ye G, Lin H, Chen S, et al. Environmental contamination of SARS-CoV-2 in healthcare
 420 premises. The Journal of infection, **2020**:
- Wang J, Feng H, Zhang S, et al. SARS-CoV-2 RNA detection of hospital isolation wards
 hygiene monitoring during the Coronavirus Disease 2019 outbreak in a Chinese
 hospital. International journal of infectious diseases : IJID : official publication of the
 International Society for Infectious Diseases, 2020; 94: 103-6.
- 425 11. Guo ZD, Wang ZY, Zhang SF, et al. Aerosol and Surface Distribution of Severe Acute
 426 Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020.
 427 Emerging infectious diseases, 2020; 26:
- 428 12. Ong SWX, Tan YK, Chia PY, et al. Air, Surface Environmental, and Personal Protective
 429 Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2
 430 (SARS-CoV-2) From a Symptomatic Patient. Jama, **2020**; 323: 1610-2.
- 43113.Liu Y, Ning Z, Chen Y, et al. Aerodynamic analysis of SARS-CoV-2 in two Wuhan432hospitals. Nature, **2020**:
- 433 14. Colaneri M, Seminari E, Novati S, et al. SARS-CoV-2 RNA contamination of inanimate
 434 surfaces and virus viability in a health care emergency unit. Clinical microbiology and

435		infection : the official publication of the European Society of Clinical Microbiology
436		and Infectious Diseases, 2020 :
437	15.	Chia PY, Coleman KK, Tan YK, et al. Detection of air and surface contamination by
438		SARS-CoV-2 in hospital rooms of infected patients. Nature communications, 2020;
439		11: 2800.
440	16.	Santarpia JL, Rivera DN, Herrera V, et al. Transmission Potential of SARS-CoV-2 in
441		Viral Shedding Observed at the University of Nebraska Medical Center. medRxiv,
442		2020 : 2020.03.23.20039446.
443	17.	Evans S, Agnew E, Vynnycky E, Robotham JV. The impact of testing and infection
444		prevention and control strategies on within-hospital transmission dynamics of
445		COVID-19 in English hospitals. medRxiv, 2020 : 2020.05.12.20095562.
446	18.	Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-
447		nCoV) by real-time RT-PCR. Euro surveillance : bulletin Europeen sur les maladies
448		transmissibles = European communicable disease bulletin, 2020 ; 25:
449	19.	Otter JA, Yezli S, French GL. The role played by contaminated surfaces in the
450		transmission of nosocomial pathogens. Infection control and hospital epidemiology,
451		2011 ; 32: 687-99.
452	20.	Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: low risk of
453		bio-aerosol dispersion. The European respiratory journal, 2020 :
454	21.	Chow VLY, Chan JYW, Ho VWY, et al. Tracheostomy during COVID-19 pandemic-
455		Novel approach. Head & neck, 2020 :
456	22.	Thamboo A, Lea J, Sommer DD, et al. Clinical evidence based review and
457		recommendations of aerosol generating medical procedures in otolaryngology -
458		head and neck surgery during the COVID-19 pandemic. Journal of otolaryngology -
459		head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-
460	22	faciale, 2020 ; 49: 28.
461	23.	Lui RN, Wong SH, Sánchez-Luna SA, et al. Overview of guidance for endoscopy during
462 462		the coronavirus disease 2019 pandemic. Journal of gastroenterology and hepatology,
463 464	24.	2020 ; 35: 749-59. PHE. COVID-19: infection prevention and control guidance
464 465	24.	https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attac
466		hment data/file/886668/COVID-
467		19 Infection prevention and control guidance complete.pdf. 2020:
468	25.	Garcia Godoy LR, Jones AE, Anderson TN, et al. Facial protection for healthcare
469	23.	workers during pandemics: a scoping review. BMJ global health, 2020 ; 5:
470	26.	Radovanovic D, Rizzi M, Pini S, Saad M, Chiumello DA, Santus P. Helmet CPAP to
471	20.	Treat Acute Hypoxemic Respiratory Failure in Patients with COVID-19: A
472		Management Strategy Proposal. Journal of clinical medicine, 2020 ; 9:
473	27.	David AP, Jiam NT, Reither JM, Gurrola JG, 2nd, Aghi M, El-Sayed IH. Endoscopic Skull
474		Base and Transoral Surgery During the COVID-19 Pandemic: Minimizing Droplet
475		Spread with a Negative-Pressure Otolaryngology Viral Isolation Drape (NOVID). Head
476		& neck, 2020 :
477	28.	Hirschmann MT, Hart A, Henckel J, Sadoghi P, Seil R, Mouton C. COVID-19
478	-	coronavirus: recommended personal protective equipment for the orthopaedic and
479		trauma surgeon. Knee surgery, sports traumatology, arthroscopy : official journal of
480		the ESSKA, 2020 : 1-9.
481		

Table 1. PCR results from surface and air samples	Table 1	PCR results	from	surface	and	air	samples
---	---------	-------------	------	---------	-----	-----	---------

				SURF	ACE SAN	IPLES				AIR SAMPLES	
		Total	positive	%positive	suspect	%suspect	positive or suspect	% positive or suspect	Result	Concentration (copies/m ³)	Notes
Cohort ward A	Staff room	6	0	0.0	2	33.3	2	33.3	Negative		
	Nurse station	6	1	16.7	3	50.0	4	66.7	Negative		
	Toilet B (outside the patients' bay)	6	0	0.0	2	33.3	2	33.3	Negative		
	Cohort bay B	6	3	50.0	2	33.3	5	83.3	Positive	7048	
Cohort ward B	Staff room	4	0	0.0	0	0.0	0	0.0	Negative		
	Patients' toilet (in the ward)	7	0	0.0	1	14.3	1	14.3	Suspect	464	
	Male bay	12	1	8.3	4	33.3	5	41.7	Suspect	1335	
	Male bay (side room)	8	2	25.0	5	62.5	7	87.5	Suspect	163	
Adult acute admission unit	Ward managers office	5	1	20.0	2	40.0	3	60.0	Negative		
	Nurse station	7	0	0.0	5	71.4	5	71.4	Positive	404	
	Patient bay 2	8	0	0.0	2	25.0	2	25.0	Negative		
	Patient bay 1	10	0	0.0	8	80.0	8	80.0	Negative		
Adult emergency department	'Green' majors	10	1	10.0	5	50.0	6	60.0	Negative		
	Nurse station	4	2	50.0	0	0.0	2	50.0	Negative		
	Ambulatory waiting	3	2	66.7	1	33.3	3	100.0	Negative		
	Patient assessment cubicles	3	0	0.0	1	33.3	1	33.3			
	Male toilet (next to the nurse station)	2	0	0.0	1	50.0	1	50.0			
	Resus bay (last patient > 2 hours)	10	0	0.0	4	40.0	4	40.0	Suspect	35	
Hospital public areas	QEQM main entrance	7	1	14.3	4	57.1	5	71.4	Suspect	1574	
	Male toilet at QEQM main entrance	7	1	14.3	3	42.9	4	57.1	Suspect	1545	
	Lift area QEQM ground floor	10	0	0.0	4	40.0	4	40.0	Negative		
Temporary CPAP ward	Nurse station	5	1	20.0	2	40.0	3	60.0	Suspect	1922	
	CPAP unit	19	2	10.5	12	63.2	14	73.7	Suspect	31	< 1m from 2 patients
									Negative		> 2 m from patients
	PPE doffing area	5	0	0.0	2	40.0	2	40.0	Negative		
Adult ICU	Staff room	10	0	0.0	6	60.0	6	60.0	Suspect	249	
	Nurse station inside ICU	6	1	16.7	0	0.0	1	16.7	Negative		
	Bay area	11	0	0.0	5	45.5	5	45.5	Suspect	164	
	Side room bay area	8	2	25.0	4	50.0	6	75.0	Suspect	307	
Theatres	Theatres	13	2	15.4	1	7.7	3	23.1	Negative		Before tracheostomy
				·					Negative		During tracheostomy
									Suspect	1163	During tracheostomy
									Negative		During tracheostomy
	Total	218	23	10.6	91	41.7	114	52.3	2/31 (6.4%) positive; 12/3	1 (38.7%) suspect

Table 2: Viability of SARS-CoV-2 dried onto steel or plastic surfaces from a dilution series; viability determined through RT-PCR from cultures immediately after drying, 0 days post inoculation (dpi) with Vero E6 cells compared with after culture (7 dpi). Means and standard deviations of Ct values are shown.

	Steel surface		Plastic surface	Plastic surface				
Inoculum (PFU)	After drying (C	Ct) After culture (Ct)	After drying (Ct)	After culture (Ct)				
41.25	26.23 ± 0.30	12.65 ± 0.51 Pos	25.95 ± 0.06	11.16 ± 0.19 Pos				
4.125	29.27 ± 0.04	12.86 ± 0.01 Pos	29.51 ± 0.29	12.58 ± 1.47 Pos				
0.4125	32.54 ± 0.06	36.48 ± 1.80 Neg	32.67 ± 0.07	37.39 ± 0.21 Neg				
0.04125	39.22 ± 5.13	41.33 ± 3.45 Neg	36.55 ± 0.23	39.76 ± 4.61 Neg				

FIGURE LEGENDS

Figure 1. Proportion of environmental samples suspected or positive by item sampled. The number of the x axis represented the number of each item sampled.

Figure 2. SARS-CoV-19 E gene copy number from surface swabs. The quantity of E gene copy number per swab is shown. Suspect samples = blue dots; positive samples = red dots; negative samples = black dots.

Supplemental Figure 1: Trends in daily number of inpatients with COVID-19; the grey box indicates when surface and air samples were collected









